Porgaviximab/Larcaviximab/Cosfroviximab | Interleukin Related interleukin-related.com

Product Name :
Porgaviximab/Larcaviximab/Cosfroviximab

Search keywords :
Cosfroviximab

drugId :
null

Target Vo:
Envelope glycoprotein

Target Vo Short Name :
GP

Moa_Name:
Envelope glycoprotein inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Mapp Biopharmaceutical

Active Company_Name :
Mapp Biopharmaceutical

Active Indication_Name:
Hemorrhagic Fever, Ebola

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Integrin beta 3 Rabbit mAb Cancer
Cemiplimab Epigenetic Reader Domain
AMPK alpha 1 Antibody: AMPK alpha 1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 64 kDa, targeting to AMPK alpha 1. It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts